Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
SAN DIEGO, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of ...
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - CervoMed ( NASDAQ:CRVO ) , Ascentage Pharma Group ( NASDAQ:AAPG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Monumental Sports & Entertainment and Ticketmaster Announce Founding Partnership to Redefine the Fan Experience at MSE's Next-Generation Arena - Live Nation Entertainment ( NYSE:LYV )
Industry-leading ticketing partner to power innovative, seamless fan journey across Capitals,Wizards, Mystics, and other world-class events at downtown D.C. arena with advanced technology,personalization, and media integration
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in November Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Vanda Pharmaceuticals ( VNDA ) Reports Q3 Loss, Misses Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -22.58% and -6.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
SAN DIEGO, Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and ...
Jim Cramer: Cameco Is A Good Company, Recommends Apollo - Apollo Asset Management ( NYSE:APO ) , Cameco ( NYSE:CCJ )
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Apollo Global Management ( NYSE:APO ) . Apollo, on Oct. 6, announced that its managed funds agreed to acquire Eagle Creek Renewable Energy, one of the largest U.S. hydroelectric power platforms.
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
SAN DIEGO, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in ...
New York Islanders Name Vanda Pharmaceuticals as Team's Jersey Patch Partner in Milestone NHL Agreement
Vanda Logo to Debut October 9 Against Penguins BELMONT PARK, N.Y., Oct. 8, 2025 /PRNewswire/ -- The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team's exclusive jersey patch partner.
AnaptysBio Charts Path To Split Into Two Companies By 2026 - AnaptysBio ( NASDAQ:ANAB )
AnaptysBio, Inc. ( NASDAQ:ANAB ) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
SAN DIEGO, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its Board of Directors approved plans to explore separating its business into two independent, ...
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
SAN DIEGO, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on ...
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in September Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive ...
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
Vanda ( VNDA ) Q2 Revenue Rises 4%
Vanda Pharmaceuticals ( NASDAQ:VNDA ) , a pharmaceutical company focused on central nervous system and rare disease treatments, reported financial results for Q2 2025 on July 31, 2025. The most important news was a GAAP net loss of $27.2 million for Q2 2025, driven by sharply higher operating ...
Vanda Pharmaceuticals ( VNDA ) Reports Q2 Loss, Misses Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. ( SAGE ) Reports Q2 Loss, Beats Revenue Estimates
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Legend Biotech ( LEGN ) Surges 6.0%: Is This an Indication of Further Gains?
Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vanda Pharmaceuticals ( VNDA ) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 9.09% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, May 05, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business ...
Vanda Pharmaceuticals ( VNDA ) Reports Q4 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Vanda Pharmaceuticals Inc. ( Vanda ) ( Nasdaq: VNDA ) and AnaptysBio, Inc. ( Anaptys ) ( Nasdaq: ANAB ) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ( IL-36R ...
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Vanda Pharma ( NASDAQ:VNDA )
FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide long-term safety data to resubmit the application.
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
New Strong Buy Stocks for November 14th
VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Vanda Pharma ( NASDAQ:VNDA )
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC )
Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter to its new drug application ( NDA ) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis. Shares of the company were down 6.1% on Sept. 19 following the ...
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
A regulator's decision drained the market's enthusiasm for the company.
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis ...
Why Is Vanda Pharmaceuticals Stock Falling On Thursday? - Vanda Pharma ( NASDAQ:VNDA )
Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.'s VNDA New Drug Application ( NDA ) of tradipitant for symptoms in gastroparesis, providing Vanda with a Complete Response Letter ( CRL ) .
Vanda Pharmaceuticals ( NASDAQ:VNDA ) Earns Hold Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA - Free Report ) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company's stock. Separately, Cantor Fitzgerald assumed coverage on shares of Vanda Pharmaceuticals in a ...
Vanda Pharmaceuticals ( NASDAQ:VNDA ) Now Covered by Analysts at StockNews.com
Equities researchers at StockNews.com started coverage on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA - Get Free Report ) in a research note issued to investors on Friday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com Initiates Coverage on Vanda Pharmaceuticals ( NASDAQ:VNDA )
Equities researchers at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA - Get Free Report ) in a research report issued on Thursday. The firm set a "hold" rating on the biopharmaceutical company's stock. Shares of VNDA stock opened at $5.36 on Thursday.
What's Going On With Vanda Pharmaceuticals Shares Today? - Vanda Pharma ( NASDAQ:VNDA )
Vanda Pharmaceuticals Inc. VNDA shares are trading lower after Future Pak withdrew its proposal to purchase the company.
Vanda Pharmaceuticals ( NASDAQ:VNDA ) Coverage Initiated by Analysts at StockNews.com
StockNews.com started coverage on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA - Get Free Report ) in a research report issued on Wednesday. The firm set a "hold" rating on the biopharmaceutical company's stock. VNDA opened at $6.14 on Wednesday.
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Vuzix ( NASDAQ:VUZI )
Shares of Vuzix Corporation VUZI rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session.
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Vanda Pharma ( NASDAQ:VNDA )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday. Shares of Vanda Pharmaceuticals Inc. VNDA fell sharply in today's pre-market trading after the company rejected unsolicited takeover bids, citing undervaluation.
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best ... PR ...
